Literature DB >> 33134769

Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions.

Srikanth R Ambati1, Emily K Slotkin1, Edna Chow-Maneval1, Ellen M Basu1.   

Abstract

Year:  2018        PMID: 33134769      PMCID: PMC7594679          DOI: 10.1200/PO.18.00095

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


× No keyword cloud information.
  25 in total

1.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

Authors:  James E Butrynski; David R D'Adamo; Jason L Hornick; Paola Dal Cin; Cristina R Antonescu; Suresh C Jhanwar; Marc Ladanyi; Marzia Capelletti; Scott J Rodig; Nikhil Ramaiya; Eunice L Kwak; Jeffrey W Clark; Keith D Wilner; James G Christensen; Pasi A Jänne; Robert G Maki; George D Demetri; Geoffrey I Shapiro
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

2.  Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Authors:  Alexander Drilon; Salvatore Siena; Sai-Hong Ignatius Ou; Manish Patel; Myung Ju Ahn; Jeeyun Lee; Todd M Bauer; Anna F Farago; Jennifer J Wheler; Stephen V Liu; Robert Doebele; Laura Giannetta; Giulio Cerea; Giovanna Marrapese; Michele Schirru; Alessio Amatu; Katia Bencardino; Laura Palmeri; Andrea Sartore-Bianchi; Angelo Vanzulli; Sara Cresta; Silvia Damian; Matteo Duca; Elena Ardini; Gang Li; Jason Christiansen; Karey Kowalski; Ann D Johnson; Rupal Patel; David Luo; Edna Chow-Maneval; Zachary Hornby; Pratik S Multani; Alice T Shaw; Filippo G De Braud
Journal:  Cancer Discov       Date:  2017-02-09       Impact factor: 39.397

3.  Identification of NTRK fusions in pediatric mesenchymal tumors.

Authors:  Dean Pavlick; Alexa B Schrock; Denise Malicki; Philip J Stephens; Dennis J Kuo; Hyunah Ahn; Brian Turpin; Justin M Allen; Mark Rosenzweig; Kamran Badizadegan; Jeffrey S Ross; Vincent A Miller; Victor Wong; Siraj M Ali
Journal:  Pediatr Blood Cancer       Date:  2017-01-18       Impact factor: 3.167

4.  Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Margaret von Mehren; R Lor Randall; Robert S Benjamin; Sarah Boles; Marilyn M Bui; Kristen N Ganjoo; Suzanne George; Ricardo J Gonzalez; Martin J Heslin; John M Kane; Vicki Keedy; Edward Kim; Henry Koon; Joel Mayerson; Martin McCarter; Sean V McGarry; Christian Meyer; Zachary S Morris; Richard J O'Donnell; Alberto S Pappo; I Benjamin Paz; Ivy A Petersen; John D Pfeifer; Richard F Riedel; Bernice Ruo; Scott Schuetze; William D Tap; Jeffrey D Wayne; Mary Anne Bergman; Jillian L Scavone
Journal:  J Natl Compr Canc Netw       Date:  2018-05       Impact factor: 11.908

5.  Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.

Authors:  Elena Ardini; Maria Menichincheri; Patrizia Banfi; Roberta Bosotti; Cristina De Ponti; Romana Pulci; Dario Ballinari; Marina Ciomei; Gemma Texido; Anna Degrassi; Nilla Avanzi; Nadia Amboldi; Maria Beatrice Saccardo; Daniele Casero; Paolo Orsini; Tiziano Bandiera; Luca Mologni; David Anderson; Ge Wei; Jason Harris; Jean-Michel Vernier; Gang Li; Eduard Felder; Daniele Donati; Antonella Isacchi; Enrico Pesenti; Paola Magnaghi; Arturo Galvani
Journal:  Mol Cancer Ther       Date:  2016-03-03       Impact factor: 6.261

6.  Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene.

Authors:  Masafumi Saiki; Fumiyoshi Ohyanagi; Ryo Ariyasu; Junji Koyama; Tomoaki Sonoda; Shingo Nishikawa; Satoru Kitazono; Noriko Yanagitani; Atsushi Horiike; Hironori Ninomiya; Yuichi Ishikawa; Makoto Nishio
Journal:  Jpn J Clin Oncol       Date:  2017-12-01       Impact factor: 3.019

7.  Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.

Authors:  A S Mansfield; S J Murphy; F R Harris; S I Robinson; R S Marks; S H Johnson; J B Smadbeck; G C Halling; E S Yi; D Wigle; G Vasmatzis; J Jen
Journal:  Ann Oncol       Date:  2016-10-14       Impact factor: 32.976

8.  What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).

Authors:  A Drilon; G Li; S Dogan; M Gounder; R Shen; M Arcila; L Wang; D M Hyman; J Hechtman; G Wei; N R Cam; J Christiansen; D Luo; E C Maneval; T Bauer; M Patel; S V Liu; S H I Ou; A Farago; A Shaw; R F Shoemaker; J Lim; Z Hornby; P Multani; M Ladanyi; M Berger; N Katabi; R Ghossein; A L Ho
Journal:  Ann Oncol       Date:  2016-02-15       Impact factor: 32.976

9.  Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.

Authors:  Andrea Sartore-Bianchi; Elena Ardini; Roberta Bosotti; Alessio Amatu; Emanuele Valtorta; Alessio Somaschini; Laura Raddrizzani; Laura Palmeri; Patrizia Banfi; Erica Bonazzina; Sandra Misale; Giovanna Marrapese; Antonella Leone; Rachele Alzani; David Luo; Zachary Hornby; Jonathan Lim; Silvio Veronese; Angelo Vanzulli; Alberto Bardelli; Marcella Martignoni; Cristina Davite; Arturo Galvani; Antonella Isacchi; Salvatore Siena
Journal:  J Natl Cancer Inst       Date:  2015-11-12       Impact factor: 13.506

10.  Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.

Authors:  Julie A Vendrell; Sylvie Taviaux; Benoît Béganton; Sylvain Godreuil; Patricia Audran; David Grand; Estelle Clermont; Isabelle Serre; Vanessa Szablewski; Peter Coopman; Julien Mazières; Valérie Costes; Jean-Louis Pujol; Pierre Brousset; Isabelle Rouquette; Jérôme Solassol
Journal:  Sci Rep       Date:  2017-10-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.